.jpg){kind=small}
Na Tajvanu je več kot 50 % bolnikov za rakom na prostati uporabilo tradicionalno kitajsko medicino (TKM). Vendar vseeno ostaja dolgoročna klinična učinkovitost TKM pri bolnikih za rakom na prostati nejasna. Zato je skupina zdravnikov in raziskovalcev preučevala odnos med rabo TKM in stopnjo preživetja pacientov, ki bolehajo za rakom na prostati.
Retrospektivna kohortna raziskava, opravljena po vsej državi, je bila izvedena v letih med 1998 in 2003, ki je vključevala bazo podatkov raziskave Tajvanskega nacionalnega zdravstvenega zavarovanja (Taiwan National Health Insurance). To je prva in največja študija, ki je ocenjevala odnos med rabo TKM in preživetjem bolnikov za rakom na prostati. Pacienti so bili klasificirani kot uporabniki ali neuporabniki TKM in so bili opazovani vse od dneva diagnoze raka na prostati do smrti oz. konca leta 2012. V tej nacionalni raziskavi je so povprečno 8 let sledili preko 1000 pacientom. Bolniki za rakom na prostati, ki so prejemali TKM zdravljenja več kot 50 dni, so imeli manjše smrtno tveganje kot tisti, ki jih niso. Po opazovanju uporabnikov TKM z metastatičnim rakom na prostati so ravno ti doživeli najvidnejše izboljšanje preživetja v primerjavi z neuporabniki TKM.
Potencialen mehanizem, s katerim se TKM bori proti raku, je bil postavljen v prejšnjih študijah. To so uravnavanje imunosti, vnetja, osteogeneze, hematopoeze in nevrozaščite. Glede na rezultate te študije so bile nekatere metode TKM prepoznane za koristne pri zdravljenju raka na prostati (tj. Chai-Hu-Jia-Long-Gu-Mu-Li-Tang in Ba-Wei-Di-Huang-Wan) in so po kasnejših kontrolnih pregledih zvišale stopnjo preživetja bolnikov za rakom na prostati.
V sedanji študiji je TKM formula, Chai-Hu-Jia-Long-Gu-Mu-Li-Tang, imela najvidneje povzročila zvišano stopnjo preživetja pri pacientih z metastatičnim rakom na prostati. Chai-Hu-Jia-Long-Gu-Mu-Li-Tang je bil uporabljen za lajšanje simptomov hipogonadizma, kar vključuje nespečnost, vročinske oblive in erektilno disfunkcijo.
Izmed 1132 izbranih bolnikov za rakom na prostati, je bilo 730 (64,5 %) uporabnikov TKM oz. 402 (35,5 %) neuporabnikov TKM. Mišljena dobra za ponovni pregled je bilo 8,38 let in poročano je bilo o 292 (25,8 %) smrti. Stopnja smrtnosti TKM uporabnikov (21,9 %) se je primerjala z neuporabniki (32,8 %). Pri pacientih, ki so se TKM poslužili za dalj časa in predvsem pri pacientih, ki so se poslužili TKM za 200 ali več dni, je bilo opaženo nižje smrtno tveganje. TKM uporabniki z metastatičnim rakom na prostati so imeli vidneje nižje razmerje nevarnosti kot neuporabniki. Chai-Hu-Jia-Long-Gu-Mu-Li-Tang je bila najvidnejša TKM formula za izboljševanje preživetja pri pacitentih z metastatičnim rakom na prostati.
Rezultat namiguje, da je morda dopolnilna TKM terapija povezana z znižanjem tveganja za smrt pri pacientih z metastatičnim rakom na prostati.
Celoten članek lahko najdete tukaj: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979842/
prevod: Tanja Topić
Complementary traditional Chinese medicine therapy improves survival in patients with metastatic prostate cancer
More than 50% of prostate cancer patients have used traditional Chinese medicine (TCM) in Taiwan. However, the long-term clinical efficiency of TCM in prostate cancer patients remains unclear. Therefore, a group of doctors and researchers investigated the relationship between TCM use and the survival of prostate cancer patients.
A retrospective nationwide cohort study of prostate cancer patients was conducted between 1998 and 2003 using the Taiwan National Health Insurance Research Database. This is the first and largest study to evaluate the relationship between TCM use and survival of prostate cancer patients.Patients were classified as TCM users or nonusers, and monitored from the day of prostate cancer diagnosis to death or end of 2012. Over 1000 patients were followed up for an average of 8 years in a retrospective nationwide cohort study. Prostate cancer patients who received TCM treatments for >50 days had a lower mortality risk compared with nonusers. TCM users with metastatic prostate cancer were observed to have the most significant improvement in survival compared with TCM nonusers.
The potential mechanisms by which TCMs act against cancer have been established in previous studies, such as modulation of immunity, inflammation,osteogenesis, hematopoiesis, and neuroprotection. According to the results of this study, some TCMs that were found to be beneficial for prostate cancer treatment (i.e., Chai-Hu-Jia-Long-Gu-Mu-Li-Tang and Ba-Wei-Di-Huang-Wan) improved the survival rate of prostate cancer patients in long-term follow-up.
In the present study, the TCM formula, Chai-Hu-Jia-Long-Gu-Mu-Li-Tang, had the most significantly improved survival rate in metastatic prostate cancer patients. Chai-Hu-Jia-Long-Gu-Mu-Li-Tang was used to relieve symptoms of hypogonadism, including insomnia, hot flashes, and erectile dysfunction.
Of the 1132 selected prostate cancer patients, 730 (64.5%) and 402 (35.5%) were TCM users and nonusers, respectively. The mean follow-up period was 8.38 years, and 292 (25.8%) deaths were reported. TCM users had a decreased mortality rate (21.9%) compared with nonusers (32.8%). A lower death risk was observed with longer TCM use, especially in patients who used TCM for ≧200 days. TCM users with metastatic prostate cancer had a significant lower hazard ratio than nonusers. Chai-Hu-Jia-Long-Gu-Mu-Li-Tang was the most significant TCM formula for improving survival in metastatic prostate cancer.
The result suggested that complementary TCM therapy might be associated with a reduced risk of death in metastatic prostate cancer patients.
Full text can be founded here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979842/
Kommentare